Kyle D. Holen

4.3k total citations
126 papers, 3.2k citations indexed

About

Kyle D. Holen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Kyle D. Holen has authored 126 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 25 papers in Molecular Biology. Recurrent topics in Kyle D. Holen's work include Cancer Treatment and Pharmacology (37 papers), Colorectal Cancer Treatments and Studies (33 papers) and Glioma Diagnosis and Treatment (21 papers). Kyle D. Holen is often cited by papers focused on Cancer Treatment and Pharmacology (37 papers), Colorectal Cancer Treatments and Studies (33 papers) and Glioma Diagnosis and Treatment (21 papers). Kyle D. Holen collaborates with scholars based in United States, Australia and Netherlands. Kyle D. Holen's co-authors include Leonard B. Saltz, Herbert Chen, George Wilding, Glenn Liu, Charles Erlichman, Joel Picus, Noelle K. LoConte, Ellen Hollywood, Axel-Rainer Hanauske and Sam Joseph Lubner and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Cancer.

In The Last Decade

Kyle D. Holen

125 papers receiving 3.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kyle D. Holen United States	31	1.8k	1.1k	657	479	451	126	3.2k
Douglas K. Graham United States	37	997 0.5×	1.4k 1.2×	308 0.5×	347 0.7×	478 1.1×	128	4.7k
Maurizio Voi United States	25	1.7k 0.9×	1.0k 0.9×	601 0.9×	805 1.7×	132 0.3×	68	3.1k
John Sarantopoulos United States	28	1.3k 0.7×	1.6k 1.4×	413 0.6×	528 1.1×	136 0.3×	143	3.2k
Ben Markman Australia	24	1.2k 0.7×	1.3k 1.2×	238 0.4×	489 1.0×	307 0.7×	75	2.5k
Colin D. Weekes United States	28	2.1k 1.2×	1.4k 1.2×	206 0.3×	634 1.3×	341 0.8×	144	3.5k
N.V. Rajeshkumar United States	29	2.8k 1.5×	1.9k 1.7×	569 0.9×	480 1.0×	393 0.9×	43	4.3k
Jan Willem B. de Groot Netherlands	27	1.9k 1.0×	1.5k 1.3×	442 0.7×	367 0.8×	361 0.8×	94	3.2k
T.R. Jeffry Evans United Kingdom	36	1.9k 1.1×	1.8k 1.6×	369 0.6×	686 1.4×	440 1.0×	107	4.4k
Juanita Lopez United Kingdom	28	2.6k 1.4×	1.9k 1.7×	314 0.5×	1.3k 2.7×	404 0.9×	144	4.9k
Neda Kalhor United States	32	1.9k 1.1×	1000 0.9×	329 0.5×	1.9k 4.0×	642 1.4×	118	4.1k

Countries citing papers authored by Kyle D. Holen

Since Specialization

Citations

This map shows the geographic impact of Kyle D. Holen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyle D. Holen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyle D. Holen more than expected).

Fields of papers citing papers by Kyle D. Holen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyle D. Holen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyle D. Holen. The network helps show where Kyle D. Holen may publish in the future.

Co-authorship network of co-authors of Kyle D. Holen

This figure shows the co-authorship network connecting the top 25 collaborators of Kyle D. Holen. A scholar is included among the top collaborators of Kyle D. Holen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyle D. Holen. Kyle D. Holen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gan, Hui, Matthew Burge, Benjamin Solomon, et al.. (2021). A Phase 1 and Biodistribution Study of ABT-806i, an ¹¹¹In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806. Journal of Nuclear Medicine. 62(6). 787–794. 15 indexed citations

Lassman, Andrew B., Lisa Roberts-Rapp, И. А. Соколова, et al.. (2019). Comparison of Biomarker Assays for EGFR : Implications for Precision Medicine in Patients with Glioblastoma. Clinical Cancer Research. 25(11). 3259–3265. 25 indexed citations

Gan, Hui, Matthew Burge, Benjamin Solomon, et al.. (2017). A Phase 1 and Biodistribution Study of Abt-806I, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-Egfr Antibody Abt-806. Internal Medicine Journal. 47. 13–13. 2 indexed citations

Bent, Martin J. van den, Lisa Roberts-Rapp, Peter Ansell, et al.. (2017). Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized clinical trials in glioblastoma. Annals of Oncology. 28. v110–v110. 1 indexed citations

Mudd, Sarah R., Robert A. Comley, Mats Bergström, et al.. (2016). Molecular imaging in oncology drug development. Drug Discovery Today. 22(1). 140–147. 11 indexed citations

Reardon, David A., Andrew B. Lassman, Martin J. van den Bent, et al.. (2016). Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro-Oncology. 19(7). now257–now257. 86 indexed citations

Mehta, Minesh P., Ding Wang, Fen Wang, et al.. (2015). Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study. Journal of Neuro-Oncology. 122(2). 409–417. 75 indexed citations

LoConte, Noelle K., Albiruni R. Abdul Razak, Percy Ivy, et al.. (2014). A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Investigational New Drugs. 33(1). 169–176. 33 indexed citations

Schelman, William R., Anne M. Traynor, Kyle D. Holen, et al.. (2013). A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Investigational New Drugs. 31(6). 1539–1546. 24 indexed citations

10.

LoConte, Noelle K., Kyle D. Holen, William R. Schelman, et al.. (2012). A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Investigational New Drugs. 31(4). 943–948. 9 indexed citations

11.

Holen, Kyle D., Renata Jaskula‐Sztul, Daniel Mulkerin, et al.. (2011). A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma. The Oncologist. 16(6). 835–843. 72 indexed citations

12.

Chung, Vincent, Elisabeth I. Heath, William R. Schelman, et al.. (2011). First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer. Cancer Chemotherapy and Pharmacology. 69(3). 733–741. 66 indexed citations

13.

Fleming, Ronald A., Carolyn J. Bowen, Mohammed M. Dar, et al.. (2011). A Phase I Study of Capecitabine, Oxaliplatin, and Lapatinib in Metastatic or Advanced Solid Tumors. Clinical Colorectal Cancer. 10(1). 57–62. 7 indexed citations

14.

Holen, Kyle D., Robert S. DiPaola, Glenn Liu, et al.. (2011). A phase I trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumors. Investigational New Drugs. 30(3). 1088–1095. 50 indexed citations

15.

Lubner, Sam Joseph, Noelle K. LoConte, Kyle D. Holen, et al.. (2010). A Phase II Study of Oxaliplatin, 5-Fluorouracil, Leucovorin, and High-Dose Capecitabine in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 9(3). 157–161. 6 indexed citations

16.

Alberti, Dona, William R. Schelman, Jill Kolesar, et al.. (2010). The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology. 66(5). 973–980. 17 indexed citations

17.

Chan, Emily, Daniel Mulkerin, Mace L. Rothenberg, et al.. (2008). A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. Investigational New Drugs. 26(3). 241–247. 28 indexed citations

18.

Holen, Kyle D., et al.. (2007). Treatment with Panitumumab After a Severe Infusion Reaction to Cetuximab in a Patient with Metastatic Colorectal Cancer: A Case Report. Clinical Colorectal Cancer. 6(7). 529–531. 30 indexed citations

19.

Kolesar, Jill, William R. Schelman, Peter Geiger, et al.. (2007). Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine®. Journal of Inorganic Biochemistry. 102(4). 693–698. 29 indexed citations

20.

Holen, Kyle D. & Leonard B. Saltz. (2001). New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. The Lancet Oncology. 2(5). 290–297. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact